Business
Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET
Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in Long COVID Now Complete Launch of New Suite of PCR Tests at Provista Underway, Including MonkeyPox Saliva Testing NEW YORK, NY, and TEL AVIV, ISRAEL, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today reported financial results for the second quarter of 2022 ended June 30, 2022, and announced a business update conference call to be held on Tuesday, August 23, 2022, at 8:30am ET. Conference call details provided here: Todos Medical Business Update Conference Call: Time: Tuesday, August 22nd, 2022 at 8:30am ET Link:https://audience.mysequire.com/webinar-view?webinar_id=3c4bfea0-1a6b-4ca5-b5db-031e3dc6e24c   Meeting ID: 94969370486 Passcode: 593560 Optional dial-in: +1-719-359-4580 “Todos’ diagnostics focus for the first half of 2022 was really about completing the transition from primarily being a company that generates revenues by selling materials and supplies into 3rd party high-complexity CLIA labs through our Corona Diagnostics business to primarily generating revenues through the sales of testing services through our own Provista Diagnostics CLIA/CAP PCR Testing lab,” said Daniel Hirsch, Chief Financial Officer of Todos Medical. “We were able to complete that transition and have seen month-over-month growth in testing revenues at Provista throughout the second quarter of 2022, culminating with over $800,000 in revenue for the month of June 2022. Sales of our Tollovid product also became material and more consistent in the second quarter as we identified Long COVID patients as a niche market and looked to initiate our sales and marketing efforts towards the Long COVID community and generate data that could serve as the basis marketing materials and prospective clinicals studies based upon data. Given that Long COVID patients have no approved therapeutic options and rely almost exclusively on supplementation, we believe that Tollovid has a tremendous opportunity to become the supplement of choice for Long COVID.” “While the second quarter marked a period of transition for Provista, it made significant progress in preparing t...